CLDI
Calidi Biotherapeutics Inc (CLDI)
Healthcare • NYSE MKT • $0.21-2.77%
- Symbol
- CLDI
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.21
- Daily Change
- -2.77%
- Market Cap
- $3.21M
- Trailing P/E
- N/A
- Forward P/E
- -0.23
- 52W High
- $19.20
- 52W Low
- $0.19
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 1.38
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Company websiteResearch CLDI on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.